Biovie Inc. (NASDAQ:BIVI)
| Market Cap | 10.18M-31.5% |
| Revenue (ttm) | 0 |
| Net Income | -22.07M-25.8% |
| EPS | -3.20+78.6% |
| Shares Out | 8.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,039.368 |
| Open | 1.37 |
| Previous Close | 1.40 |
| Day's Range | 1.32 - 1.39 |
| 52-Week Range | 0.82 - 3.79 |
| Beta | 0.73 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
BIOVIE INC. has a live Insider Score.
Scored on 4 qualifying trades from 4 insiders in the last 90 days.
About BIVI
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BIVI stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BIVI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BIVI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BIVI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BIVI Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Clinical studies | $8.18M | 60.50% |
| Clinical teams | $5.15M | 38.11% |
| Chemistry, manufacturing and controls | $188.00K | 1.39% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-K)
U.S. Patents
New BIVI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BIVI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BIVI
| ETF | Est. Holding Size |
|---|---|
| VXFVanguard Extended Market ETF | $161.67K |
Estimated from each fund’s disclosed top holdings × AUM
BIVI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BIVI’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score